Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MENINGREF: 4CMenB Vaccine in HSCT Recipients
NCT03509051Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2019
- Primary completion
- Mar 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of meningococcal group B vaccine in Meningococcal B infection, sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Percentage of patients with Bactericidal titers > 4 to at least one component of the Bexsero vaccine. Started Jun 2019; status: completed.
02
Drugs
meningococcal group B vaccine
03
Conditions
Meningococcal B infection
Beyond the preview
Go deeper on NCT03509051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03509051.